ABSTRACT
BACKGROUND: Previous studies on cancer of unknown primary (CUP) mainly focus on treatment and prognosis in western populations and lacked clinical evaluation of different IHC markers, so this study aimed to evaluate characteristics of CUP and recommend a diagnostic strategy from a single center in China. METHODS AND RESULTS: Data of 625 patients with CUP were retrospectively collected and reviewed. The patients ranged in age from 20 to 91 years, with a female-to-male ratio of 1.3:1. The predominant histological type was poor or undifferentiated adenocarcinomas (308; 49.3%). The results of Canhelp-Origin molecular testing for the identification of the tissue of origin in 262 of 369 patients (71.0%) were considered predictable (similarity score > 45), with the most common predicted primary tumor site being the breast (57, 21.8%). Unpredictable molecular results correlated with more aggressive clinical parameters and poor survival. Thee positivity rates of several targeted antibodies (GATA3, GCDFP15, TTF1, Napsin A, and PAX8), based on the clinically predicted site, were lower than those reported for the corresponding primary tumors. Nonetheless, TRPS1 and INSM1 were reliable markers of predicted breast carcinoma (75.0%) and neuroendocrine tumors (83.3%), respectively. P16 expression, as well as HPV and EBER testing contributed significantly to the diagnosis of squamous cell carcinomas. Survival analysis revealed that older ages (> 57), ≥ 3 metastatic sites, non-squamous cell carcinomas, bone/liver/lung metastases, unpredictable molecular results, and palliative treatment correlated with poor overall survival. CONCLUSIONS: We recommend a CUP diagnostic strategy involving the use of targeted antibody panels as per histological findings that is potentially applicable in clinical practice. The markers TRPS1, INSM1, and P16 expression, as well as HPV and EBER testing are particularly valuable in this aspect. Molecular testing is also predictive of survival rates.
Subject(s)
Adenocarcinoma , Neoplasms, Unknown Primary , Papillomavirus Infections , Humans , Male , Female , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Neoplasms, Unknown Primary/pathology , Retrospective Studies , Biomarkers, Tumor/metabolism , Repressor ProteinsABSTRACT
El fibrosarcoma es la neoplasia maligna mesodérmica de más incidencia.Los autores se vieron motivados a presentar un caso clínico con esta entidad con el objetivo de enfatizar en la importancia del correcto manejo diagnóstico y terapéutico en función de la rehabilitación de estos pacientes. Se presenta un caso clínico de un paciente de 54 años de edad con antecedentes de HTA controlada, que 23 años atrás comenzó con aumento de volumen en región geniana izquierda, motivo por el que fue intervenido quirúrgicamente en los años 1987, 1991 y 2009, en otros servicios de Cirugía Máxilofacial con diagnóstico histopatológico de neurofibroma, que acudió a consulta presentando una lesión de 5 cm de diámetro, con patrón de crecimiento rápido, que sangraba espontáneamente, la cual le comprimía el globo ocular izquierdo limitándole la apertura palpebral. Luego de realizársele el estudio preoperatorio correspondiente, se decidió tratamiento quirúrgico, se obtuvo un diagnóstico concluyente a través del estudio inmunohistoquímico de fibrosarcoma de grado intermedio de diferenciación, de marcada inmunorreactividad CD34 (+, focal), Vimentina (+, focal). Se concluye que el tratamiento de esta entidad es quirúrgico, teniendo en cuenta las normas oncológicas actuales, y su enfoque terapéutico debe ser multidisciplinario en aras de lograr una correcta rehabilitación funcional y estética del paciente. La inmunohistoquímica constituye un arma diagnóstica concluyente que contribuye a instaurar tratamiento adecuado en estas lesiones.(AU)
The fibrosarcoma is the more incident mesodermic malignant neoplasm. Authors present this clinical case presenting with this entity to emphasize on the significance of the appropriate diagnostic and therapeutical management for rehabilitation of these patients. This patient is aged 54 with a history of controlled high blood pressure (HBT) who over the 23 past years begun to show an increase of volume in left genial region thus its surgical intervention in 1987, 1991 and 2009 years and came to consultation presenting with a 5 cm diameter lesion with a fast growth pattern bleeding spontaneously compressing the left ocular globe restricting the palpebral opening. After the corresponding preoperative study authors prescribed the surgical treatment obtaining a conclusive diagnosis according to a immunohistochemical study of the fibrosarcoma of intermediate degree of differentiation with a marked CD34 (+, focal) immunoreactivity, Vimentin (+,focal). We conclude that the treatment of this entity is of surgical type, taking into account the current oncology guidelines and its therapeutical approach must to be multidisciplinary to achieve the functional and aesthetic rehabilitation of the patient. The immunohistochemistry is a conclusive diagnostic tool contributing to apply the appropriate treatment in this type of lesion.(AU)
Subject(s)
Humans , Male , Middle Aged , Fibrosarcoma/diagnosis , Fibrosarcoma/surgery , Facial Neoplasms/diagnosis , Facial Neoplasms/surgery , ImmunohistochemistryABSTRACT
El fibrosarcoma es la neoplasia maligna mesodérmica de más incidencia.Los autores se vieron motivados a presentar un caso clínico con esta entidad con el objetivo de enfatizar en la importancia del correcto manejo diagnóstico y terapéutico en función de la rehabilitación de estos pacientes. Se presenta un caso clínico de un paciente de 54 años de edad con antecedentes de HTA controlada, que 23 años atrás comenzó con aumento de volumen en región geniana izquierda, motivo por el que fue intervenido quirúrgicamente en los años 1987, 1991 y 2009, en otros servicios de Cirugía Máxilofacial con diagnóstico histopatológico de neurofibroma, que acudió a consulta presentando una lesión de 5 cm de diámetro, con patrón de crecimiento rápido, que sangraba espontáneamente, la cual le comprimía el globo ocular izquierdo limitándole la apertura palpebral. Luego de realizársele el estudio preoperatorio correspondiente, se decidió tratamiento quirúrgico, se obtuvo un diagnóstico concluyente a través del estudio inmunohistoquímico de fibrosarcoma de grado intermedio de diferenciación, de marcada inmunorreactividad CD34 (+, focal), Vimentina (+, focal). Se concluye que el tratamiento de esta entidad es quirúrgico, teniendo en cuenta las normas oncológicas actuales, y su enfoque terapéutico debe ser multidisciplinario en aras de lograr una correcta rehabilitación funcional y estética del paciente. La inmunohistoquímica constituye un arma diagnóstica concluyente que contribuye a instaurar tratamiento adecuado en estas lesiones.(AU)
The fibrosarcoma is the more incident mesodermic malignant neoplasm. Authors present this clinical case presenting with this entity to emphasize on the significance of the appropriate diagnostic and therapeutical management for rehabilitation of these patients. This patient is aged 54 with a history of controlled high blood pressure (HBT) who over the 23 past years begun to show an increase of volume in left genial region thus its surgical intervention in 1987, 1991 and 2009 years and came to consultation presenting with a 5 cm diameter lesion with a fast growth pattern bleeding spontaneously compressing the left ocular globe restricting the palpebral opening. After the corresponding preoperative study authors prescribed the surgical treatment obtaining a conclusive diagnosis according to a immunohistochemical study of the fibrosarcoma of intermediate degree of differentiation with a marked CD34 (+, focal) immunoreactivity, Vimentin (+,focal). We conclude that the treatment of this entity is of surgical type, taking into account the current oncology guidelines and its therapeutical approach must to be multidisciplinary to achieve the functional and aesthetic rehabilitation of the patient. The immunohistochemistry is a conclusive diagnostic tool contributing to apply the appropriate treatment in this type of lesion(AU)
